SCHEMBL3222818

SCHEMBL3222818

CCOc1ccc2c(c1)C(C)(c1cc(C(=O)OC)ccc1Cl)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 1/20 0.44
GNRHR P30968 1/20 0.37
MAPT P10636 3/20 0.37
RECQL P46063 1/20 0.37
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 3/20 0.36
HTT P42858 2/20 0.36
HPGD P15428 1/20 0.36
VDR P11473 1/20 0.36
EPHX2 P34913 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
CYP2C19 P33261 2/20 0.35
USP2 O75604 1/20 0.35
POLB P06746 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3228428 0.93 AVPR1A (0.43) AVPR1AGNRHRMAPTRECQLALDH1A1
SCHEMBL3237022 0.91 AVPR1A (0.39) AVPR1AGNRHRMAPTRECQLALDH1A1
SCHEMBL3227311 0.91 AVPR1A (0.41) AVPR1AGNRHRMAPTRECQLALDH1A1
SCHEMBL3237015 0.90 AVPR1A (0.40) AVPR1AGNRHRMAPTRECQLALDH1A1
SCHEMBL3233628 0.90 AVPR1A (0.43) AVPR1AGNRHRMAPTRECQLALDH1A1
SCHEMBL3230272 0.90 AVPR1A (0.42) AVPR1AGNRHRMAPTRECQLALDH1A1
SCHEMBL3234467 0.90 AVPR1A (0.42) AVPR1AGNRHRMAPTRECQLALDH1A1
SCHEMBL3233778 0.89 AVPR1A (0.41) AVPR1AGNRHRMAPTRECQLALDH1A1
SCHEMBL3233812 0.88 AVPR1A (0.46) AVPR1AMAPTALDH1A1MEN1KMT2A
SCHEMBL3225093 0.87 MAPT (0.42) AVPR1AGNRHRMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097374-B1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS SANOFI AVENTIS (FR) 2010-06-09 EP claimed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US claimed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AVPR2, AVPR1A, AVPR1B AVPR1A 2/4885GNRHR 112/4885MAPT 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.